BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38211653)

  • 21. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
    Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
    Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.
    Beloueche-Babari M; Box C; Arunan V; Parkes HG; Valenti M; De Haven Brandon A; Jackson LE; Eccles SA; Leach MO
    Br J Cancer; 2015 Mar; 112(7):1206-14. PubMed ID: 25742484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
    Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
    Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A; Gibson-Corley KN; Love-Homan L; Ihejirika N; Simons AL
    Oncotarget; 2016 Nov; 7(46):76087-76100. PubMed ID: 27738319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
    Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
    Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
    Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
    Stanam A; Love-Homan L; Joseph TS; Espinosa-Cotton M; Simons AL
    Mol Oncol; 2015 Aug; 9(7):1371-83. PubMed ID: 25888065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment.
    Song X; Tang W; Peng H; Qi X; Li J
    Invest New Drugs; 2021 Oct; 39(5):1201-1212. PubMed ID: 33829354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
    Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
    Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
    [No Abstract]   [Full Text] [Related]  

  • 36. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.
    Nguyen KA; Keith MJ; Keysar SB; Hall SC; Bimali A; Jimeno A; Wang XJ; Young CD
    Mol Carcinog; 2022 Jul; 61(7):664-676. PubMed ID: 35417043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J; Li Q; Ding X; Gao Y
    Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
    Jain AP; Radhakrishnan A; Pinto S; Patel K; Kumar M; Nanjappa V; Raja R; Keshava Prasad TS; Mathur PP; Sidransky D; Chatterjee A; Gowda H
    OMICS; 2021 Sep; 25(9):605-616. PubMed ID: 34432535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
    Chakravarti N; Myers JN; Aggarwal BB
    Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.